Information Library
Results for: White Papers
To learn more about Quintiles’ services, you may broaden or narrow your search by selecting the topics at left.
- Sort by:
- Recently Added
- Title
-
Reinventing Biopharma
February 1, 2012
The biopharmaceutical industry today is facing a multifaceted “value challenge.” -
Expected Growth of Industry-Sponsored Clinical Trials in the Middle East Benchmarked on other Global Regions
February 1, 2012
The evolving business model in the biopharmaceutical industry depends on increased productivity in clinical trials. This demands lower-cost, faster and more effective clinical trial processes. -
FSPs: Ranging from Tactical to Strategic Models
January 4, 2012
Biopharma companies can choose from a range of outsourcing models as they seek to respond effectively to the ever-changing conditions in the New Health. -
Strategic Alliances
December 5, 2011
Strategic alliances with specialized external partners allow companies to increase agility and the efficiency of processes, variablize resources and raise the number of promising drug candidates in their pipeline. -
An Integrated Approach to Biosimilar Development & Commercialization
September 29, 2011
As the market for biosimilar products continues to grow, many biopharmaceutical companies trying to enter the space are struggling to overcome the unique challenges that developing such products presents. -
Partnering to Maximize Rewards in Pharmerging Markets
September 15, 2011
In the past few years so-called “pharmerging” markets have been heralded as the hottest growth area for biopharmaceutical drugs. With large populations, growing disposable income and unmet medical needs, these markets have seen doubledigit growth rates in pharmaceutical spending. -
The New Health
August 23, 2011
In 2010, Quintiles advanced the concept of the New Health, our perspective on the fast-morphing biopharma landscape, where the rules are changing on all fronts. -
Methods Matter
July 18, 2011
As healthcare decision making becomes more complex, stakeholders are demanding real-world evidence tailored to their own individual needs. -
Reinventing Biopharma
July 11, 2011
It’s not easy being a life sciences firm today. Companies in the sector have seen rising research and development (R&D) costs, in exchange for flat, or even diminishing, innovation returns. -
The Molecular Biomarker Revolution in Non-Small Cell Lung Cancer
June 23, 2011
In this new white paper Quintiles’ experts Christopher Ung, Jason Hill, Carrie Lee and Harish Dave review some of the most promising molecular pathways and targeted approaches for NSCLC, the critical role of diagnostics, and strategies to detect and address the emergence of resistance.
